[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"inflammatory-reaction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:inflammatory-reaction":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,58],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":24,"studyType":25,"phases":4,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100449993","montreal-immune-related-adverse-events-mirae-study-100449993",false,"NCT05139706","Montreal Immune-Related Adverse Events (MIRAE) Study","Montreal Database and Biorepository of Cancer Patients Treated With Immune Checkpoint Inhibitors for the Study of Immune-related Adverse Events","MIRAE","Inclusion Criteria:\n\n* \\>= 18 years of age\n* cancer patients treated with ICI therapy (e.g., anti-CTLA-4, anti-PD-1, anti-PD-L1, and combinations)\n* patients with primary autoimmune or autoinflammatory diseases that resemble immune-related adverse events (irAEs)\n* healthy volunteers with non-inflammatory disorders, and without any history of cancer\n\nExclusion Criteria:\n\n* Participants not able to provide informed consent",true,"ALL","18 Years","100 Years",{"count":22,"type":23},1000,"ESTIMATED","60 Months","OBSERVATIONAL","Immune checkpoint inhibitors (ICI) are among the most promising approaches to fighting cancer. However, a substantial percentage of patients experience off-target adverse effects in the form of mild to severe inflammation in different organs, commonly called immune-related adverse events (irAEs). irAEs can lead to treatment discontinuation, or can be life-threatening in extreme cases. The causes of irAEs are largely unknown and there are no reliable predictive biomarkers. The Montreal Immune-Related Adverse Events (MIRAE) study collects clinical information and biospecimens (blood, tissue, stool) from cancer patients treated with ICI to facilitate research on the identification of predictive biomarkers of irAEs, their causes, and the design of effective management strategies.",[28,29,30,31],"Cancer","Immune System Disorder","Inflammatory Reaction","Autoimmune Diseases",[33,34,35,36,37,38,39,40,41,42,43,44],"irAEs","ICI (ICB)","CTLA-4","PD-1","PDL-1","Pembrolizumab","Nivolumab","Ipilimumab","Cemiplimab","Atezolizumab","Avelumab","Durvalumab","RECRUITING","2026-01-30",{"date":48,"type":49},"2026-02-03","ACTUAL",{"date":51,"type":49},"2020-01-21",{"date":53,"type":23},"2030-01",{"name":55,"class":56},"Sir Mortimer B. Davis - Jewish General Hospital","OTHER",1,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":4,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":57},"100396491","sequelae-of-sars-cov-2-infections-100396491","NCT04442789","Sequelae of Sars-CoV-2 Infections","Long-term Sequelae of Severe Sars-CoV-2 Infections","Inclusion Criteria:\n\n* hospitalization due to Sars-CoV-2 infection\n\nExclusion Criteria:\n\n* under 18 years of age",{"count":66,"type":23},120,"By the end of 2019 a new coronavirus, named SARS-CoV-2, was discovered in patients with pneumonia in Wuhan, China. In the following weeks and months the virus spread globally, having a tremendous impact on global health and economy. To date, no vaccine or therapy is available. Severe courses of the infection not only affect the lungs, but also other organs like the heart, kidney, or liver. The lack of preexisting immunity might at least partially explain the affection of extra pulmonary organs not yet seen in infections due to other respiratory viruses. In this observational investigation the study group will follow up on patients that have been hospitalized due to a SARS-CoV-2 infection, and monitor sequelae in various organs, with an emphasis on the pulmo-cardiovascular system. Our that in some patients, organ damage will persist and require long-term medical care.",[69,70,30],"Lung Diseases","Cardiac Disease","2025-03-25",{"date":73,"type":49},"2025-03-30",{"date":75,"type":49},"2020-05-20",{"date":77,"type":23},"2025-12-31",{"name":79,"class":56},"University of Giessen"]